Literature DB >> 33479660

Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors.

Yan Yin1, Yuxing Sun1, Lianhua Zhao1, Jinpeng Pan1, Yangbo Feng2,3.   

Abstract

Ribosomal protein S6 kinase beta-1 (S6K1) is an attractive therapeutic target. In this study, computational analysis of five thiophene urea-based S6K1 inhibitors was performed. Molecular docking showed that the five compounds formed hydrogen bonds with residues Glu173 and Leu175 of S6K1 and hydrophobic interactions with residues Val105, Leu97 and Met225, and these interactions were key elements for the inhibitory potency of the compounds. Binding free energy (ΔG bind) decomposition analysis showed that Leu97, Glu173, Val 105, Leu175, Leu97 and Met225 contribute the most to ΔG bind. Based on the computer results, phenylpyrazole based amides (D1-D3) were designed and synthesized. Biological evaluation revealed that D2 exhibited 15.9 nM S6K1 inhibition, medium microsomal stability and desirable bioavailability. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479660      PMCID: PMC7605259          DOI: 10.1039/c9md00537d

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  18 in total

1.  Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.

Authors:  Jinpeng Pan; Yan Yin; Lianhua Zhao; Yangbo Feng
Journal:  Bioorg Med Chem       Date:  2019-02-22       Impact factor: 3.641

2.  Methionine deprivation regulates the S6K1 pathway and protein synthesis in avian QM7 myoblasts without activating the GCN2/eIF2 alpha cascade.

Authors:  Sonia Métayer-Coustard; Hamza Mameri; Iban Seiliez; Sabine Crochet; Pascale Crépieux; Yves Mercier; Pierre-André Geraert; Sophie Tesseraud
Journal:  J Nutr       Date:  2010-07-07       Impact factor: 4.798

3.  Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations.

Authors:  Tingjun Hou; Junmei Wang; Youyong Li; Wei Wang
Journal:  J Chem Inf Model       Date:  2010-11-30       Impact factor: 4.956

4.  Chroman-3-amides as potent Rho kinase inhibitors.

Authors:  Yen Ting Chen; Thomas D Bannister; Amiee Weiser; Evelyn Griffin; Li Lin; Claudia Ruiz; Michael D Cameron; Stephan Schürer; Derek Duckett; Thomas Schröter; Philip LoGrasso; Yangbo Feng
Journal:  Bioorg Med Chem Lett       Date:  2008-10-22       Impact factor: 2.823

5.  mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.

Authors:  Merav Fraenkel; Mali Ketzinel-Gilad; Yafa Ariav; Orit Pappo; Melis Karaca; Julien Castel; Marie-France Berthault; Christophe Magnan; Erol Cerasi; Nurit Kaiser; Gil Leibowitz
Journal:  Diabetes       Date:  2008-01-03       Impact factor: 9.461

6.  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.

Authors:  Yangbo Feng; Yan Yin; Amiee Weiser; Evelyn Griffin; Michael D Cameron; Li Lin; Claudia Ruiz; Stephan C Schürer; Toshihiro Inoue; P Vasanth Rao; Thomas Schröter; Philip Lograsso
Journal:  J Med Chem       Date:  2008-10-04       Impact factor: 7.446

7.  Ribosomal S6K1 in POMC and AgRP Neurons Regulates Glucose Homeostasis but Not Feeding Behavior in Mice.

Authors:  Mark A Smith; Loukia Katsouri; Elaine E Irvine; Mohammed K Hankir; Silvia M A Pedroni; Peter J Voshol; Matthew W Gordon; Agharul I Choudhury; Angela Woods; Antonio Vidal-Puig; David Carling; Dominic J Withers
Journal:  Cell Rep       Date:  2015-04-09       Impact factor: 9.423

8.  Development of organometallic S6K1 inhibitors.

Authors:  Jie Qin; Rajathees Rajaratnam; Li Feng; Jemilat Salami; Julie S Barber-Rotenberg; John Domsic; Patricia Reyes-Uribe; Haiying Liu; Weiwei Dang; Shelley L Berger; Jessie Villanueva; Eric Meggers; Ronen Marmorstein
Journal:  J Med Chem       Date:  2014-11-13       Impact factor: 7.446

9.  Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation.

Authors:  Xiulong Xu; Jing Sun; Ruilong Song; Michelle E Doscas; Ashley J Williamson; Jingsong Zhou; Jun Sun; Xinan Jiao; Xiufan Liu; Yi Li
Journal:  Oncotarget       Date:  2017-05-02

10.  Combination of pharmacophore hypothesis, genetic function approximation model, and molecular docking to identify novel inhibitors of S6K1.

Authors:  Hui Zhang; Ming-Li Xiang; Jun-Yu Liang; Tao Zeng; Xiao-Nuo Zhang; Ji Zhang; Sheng-Yong Yang
Journal:  Mol Divers       Date:  2013-08-28       Impact factor: 2.943

View more
  1 in total

1.  Screening possible drug molecules for Covid-19. The example of vanadium (III/IV/V) complex molecules with computational chemistry and molecular docking.

Authors:  Manos C Vlasiou; Kyriaki S Pafti
Journal:  Comput Toxicol       Date:  2021-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.